AdaptHealth announced second-quarter 2026 financial results with 12.7% revenue growth
Net loss was $145.3 million due to a goodwill write-down, and full-year Adjusted EBITDA guidance was lowered to $490–520 million; Diabetes Health divestiture signed for $235 million.